Enveric Biosciences, Inc. (ENVB) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Enveric Biosciences, Inc.

ENVB

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

Biotechnology

Next Earning date - 11 Aug 2025

Biotechnology

Next Earning date - 11 Aug 2025

1.27USD

0.06 ( 4.96%)

Market Closed (as of Jun 16, 20:00 EDT)

Relative Strenght

Volume Buzz

-36%

Earning Acce

Dist 52w H.

99%

Overview Chart

Quote Panel

Updated June 17, 2025

1W 3.25 % 1M -6.62 % 3M -24.85 % 1Y -87.38 %

Key Metrics

Market Cap
3.14M
Shares Outstanding
2.47M
Share in Float
2.14M
Dividende
0

Earning Date
11 Aug 2025
Price Target
1.27
Average Volume
201668
Beta
0.319

Range
1.01-173.25
Industry
Biotechnology
Website
https://www.enveric.com
Sector
Healthcare

Quote Panel

Updated June 17, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.58x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-11.1

EPS

How ENVB compares to sector?

P/E Ratio

Fundamentals

Relative Strength

ENVB

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

ENVB

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$10M

NaN%

2026-Revenue

$26.25

-2052%

2026-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-45.58
vs -40.93

Q3.23

N/A

-19.49
vs -21.89

Q4.23

N/A

-21.89
vs 7

Q1.24

N/A

-9.15
vs -11.24

Q2.24

N/A

-3.75
vs -45.58

Q3.24

N/A

-3.60
vs -19.49

Q4.24

N/A

-21.89
vs -21.89

Q1.25

N/A

-1.22
vs -9.15

Q2.25

N/A

-5.25
vs -3.75

Q3.25

N/A

-5.25
vs -3.60

Sales Growth

YoY

Current

Estimates

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

647.1K vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-100%

NA vs 647.1K

Q1.25

NA vs NA

Return on Equity

QoQ

Q2.23

-131%

-1.31
vs -0.44

Q3.23

-116%

-1.16
vs -1.31

Q4.23

-91%

-0.91
vs -1.16

Q1.24

-38%

-0.38
vs -0.91

Q2.24

-35%

-0.35
vs -0.38

Q3.24

-53%

-0.53
vs -0.35

Q4.24

-198%

-1.98
vs -0.53

Q1.25

-56%

-0.56
vs -1.98

Institutionnal Ownership

QoQ

Q1.23

12
vs 10

20%

Q2.23

14
vs 12

17%

Q3.23

14
vs 14

Q4.23

14
vs 14

Q1.24

17
vs 14

21%

Q2.24

17
vs 17

Q3.24

16
vs 17

-6%

Q4.24

19
vs 16

19%

Earnings Growth

Latest News

businesswire.com

8 hours ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

businesswire.com

8 hours ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

businesswire.com

9 hours ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

businesswire.com

9 hours ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

businesswire.com

10 hours ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

businesswire.com

16 hours ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Company Description

1.27USD

N/A

0.00x

0.58x

0.0

0.0%

$-11.1

$10M

$26.25

Earnings Growth

Latest News

Latest News

$10M

$26.25

Latest News

Company Description

1.27USD

N/A

0.00x

0.58x

0.0

0.0%

$-11.1